Tag: underwriting

TAMPA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- The board of directors of HCI Group, Inc. (NYSE: HCI) has declared a regular quarterly cash dividend in the amount of 40 cents per common share. The dividend is scheduled to be paid September 19, 2025 to shareholders of record at the close of business August 15, 2025.

FORT WASHINGTON, Pa., July 02, 2025 (GLOBE NEWSWIRE) -- Coventry, the leader and creator of the secondary market for life insurance, today released the following statement:

NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public offering of 2,482,692 shares of its common stock at a price to the public of $19.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,363,469 shares of its common stock at a price to the public of $19.4999, which represents the per share public offering price for the shares of common stock less $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to ArriVent from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $75 million. In addition, ArriVent has granted the underwriters a 30-day option to purchase up to an additional 576,923 shares of its common stock on the same terms and conditions. All of the securities are being offered by ArriVent.

SARATOGA, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares are expected to begin trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “CV.” The offering is expected to close on July 3, 2025 subject to the satisfaction of customary closing conditions.

FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $6 million prior to deducting underwriting commissions and offering expenses.

Palo Alto, California, June 30, 2025 (GLOBE NEWSWIRE) --  NMP Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 10,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one right. Each right entitles the holder to receive one-fifth (1/5) of one Class A ordinary share upon consummation of the Company’s initial business combination. In connection with the offering, $10.00 per unit will be deposited into a trust account with Continental Stock Transfer & Trust Company acting as trustee. Up to $300,000 of interest earned on the funds held in the trust account, in the aggregate, may be released to us to fund our working capital requirements.  In addition, we may withdraw interest earned on the trust to pay our income and franchise taxes, if any. The units are expected to trade on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “NMPAU” beginning on July 1, 2025. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to trade on Nasdaq under the symbols “NMP” and “NMPAR,” respectively.

SEATTLE and VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the closing of its underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 16,766,666 shares of common stock at a public offering price of $3.00 per share and accompanying warrant, which includes common warrants to purchase up to 1,766,666 shares issued upon the partial exercise by the underwriters of their option to purchase additional shares of common stock and/or accompanying warrants. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $45.0 million.